TY - JOUR
T1 - Characteristics of Ebola Virus Disease Survivor Blood and Semen in Liberia
T2 - Serology and Reverse Transcription Polymerase Chain Reaction (RT-PCR)
AU - Kofman, Aaron
AU - Linderman, Susanne
AU - Su, Kaihong
AU - Purpura, Lawrence J.
AU - Ervin, Elizabeth
AU - Brown, Shelley
AU - Morales-Betoulle, Maria
AU - Graziano, James
AU - Cannon, Deborah L.
AU - Klena, John D.
AU - Desamu-Thorpe, Rodel
AU - Fankhauser, John
AU - Orone, Romeo
AU - Moses, Soka
AU - Glaybo, Uriah
AU - Massaquoi, Moses
AU - Nyenswah, Tolbert
AU - Nichol, Stuart T.
AU - Kollie, Jomah
AU - Kiawu, Armah
AU - Freeman, Edna
AU - Giah, Giovanni
AU - Tony, Henry
AU - Faikai, Mylene
AU - Jawara, Mary
AU - Kamara, Kuku
AU - Kamara, Samuel
AU - Flowers, Benjamin
AU - Mohammed, Kromah
AU - Chiriboga, David
AU - Williams, Desmond E.
AU - Hinrichs, Steven H.
AU - Ahmed, Rafi
AU - Vonhm, Benjamin
AU - Rollin, Pierre E.
AU - Choi, Mary J.
N1 - Publisher Copyright:
© 2020 Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Introduction: Ebola virus (EBOV), species Zaire ebolavirus, may persist in the semen of male survivors of Ebola virus disease (EVD). We conducted a study of male survivors of the 2014-2016 EVD outbreak in Liberia and evaluated their immune responses to EBOV. We report here findings from the serologic testing of blood for EBOV-specific antibodies, molecular testing for EBOV in blood and semen, and serologic testing of peripheral blood mononuclear cells (PBMCs) in a subset of study participants. Methods: We tested for EBOV RNA in blood by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and for anti-EBOV-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies by enzyme-linked immunosorbent assay (ELISA) for 126 study participants. We performed PBMC analysis on a subgroup of 26 IgG-negative participants. Results: All 126 participants tested negative for EBOV RNA in blood by qRT-PCR. The blood of 26 participants tested negative for EBOV-specific IgG antibodies by ELISA. PBMCs were collected from 23/26 EBOV IgG-negative participants. Of these, 1/23 participants had PBMCs that produced anti-EBOV-specific IgG antibodies upon stimulation with EBOV-specific glycoprotein (GP) and nucleoprotein (NP) antigens. Conclusions: The blood of EVD survivors, collected when they did not have symptoms meeting the case definition for acute or relapsed EVD, is unlikely to pose a risk for EBOV transmission. We identified 1 IgM/IgG negative participant who had PBMCs that produced anti-EBOV-specific antibodies upon stimulation. Immunogenicity following acute EBOV infection may exist along a spectrum, and absence of antibody response should not be exclusionary in determining an individual's status as a survivor of EVD.
AB - Introduction: Ebola virus (EBOV), species Zaire ebolavirus, may persist in the semen of male survivors of Ebola virus disease (EVD). We conducted a study of male survivors of the 2014-2016 EVD outbreak in Liberia and evaluated their immune responses to EBOV. We report here findings from the serologic testing of blood for EBOV-specific antibodies, molecular testing for EBOV in blood and semen, and serologic testing of peripheral blood mononuclear cells (PBMCs) in a subset of study participants. Methods: We tested for EBOV RNA in blood by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and for anti-EBOV-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies by enzyme-linked immunosorbent assay (ELISA) for 126 study participants. We performed PBMC analysis on a subgroup of 26 IgG-negative participants. Results: All 126 participants tested negative for EBOV RNA in blood by qRT-PCR. The blood of 26 participants tested negative for EBOV-specific IgG antibodies by ELISA. PBMCs were collected from 23/26 EBOV IgG-negative participants. Of these, 1/23 participants had PBMCs that produced anti-EBOV-specific IgG antibodies upon stimulation with EBOV-specific glycoprotein (GP) and nucleoprotein (NP) antigens. Conclusions: The blood of EVD survivors, collected when they did not have symptoms meeting the case definition for acute or relapsed EVD, is unlikely to pose a risk for EBOV transmission. We identified 1 IgM/IgG negative participant who had PBMCs that produced anti-EBOV-specific antibodies upon stimulation. Immunogenicity following acute EBOV infection may exist along a spectrum, and absence of antibody response should not be exclusionary in determining an individual's status as a survivor of EVD.
KW - Ebola survivors
KW - immunology
KW - semen persistence
UR - http://www.scopus.com/inward/record.url?scp=85122546864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122546864&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa1331
DO - 10.1093/cid/ciaa1331
M3 - Article
C2 - 32894277
AN - SCOPUS:85122546864
SN - 1058-4838
VL - 73
SP - E3641-E3646
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -